Immatics N.V.
NASDAQ:IMTX · NASDAQ Capital Market
+$0.15 today
Vol 0.33M · Avg 0.46M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+80.44%
Period High
$11.87
Period Low
$5.09
Latest
$9.78
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.78B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.73B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.68B
Atai Beckley Inc.
NASDAQ:ATAI
$1.48B
Precigen, Inc.
NASDAQ:PGEN
$1.39B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.34B
Tourmaline Bio, Inc.
TRML
$1.23B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
What is the latest IMTX filing?
The latest filing shown is 6-K dated Jun 2, 2026.
How many recent filings does IMTX have?
Intrinsic Alpha currently shows 20 recent filings for IMTX.
Explore More
Continue the stock analysis
Jump to another research area for this company.